Basilea Pharmaceutica AG Allschwil Stock

Basilea Pharmaceutica AG Allschwil P/E 2024

Basilea Pharmaceutica AG Allschwil P/E

10.96

Ticker

BSLN.SW

ISIN

CH0011432447

WKN

A0B9GA

As of Dec 5, 2024, Basilea Pharmaceutica AG Allschwil's P/E ratio was 10.96, a -79.41% change from the 53.24 P/E ratio recorded in the previous year.

The Basilea Pharmaceutica AG Allschwil P/E history

Basilea Pharmaceutica AG Allschwil Aktienanalyse

What does Basilea Pharmaceutica AG Allschwil do?

Basilea Pharmaceutica AG is a leading biopharmaceutical company based in Basel, Switzerland. It was founded in 2000 and focuses on the research, development, and marketing of innovative drugs for the treatment of infectious diseases, cancer, and dermatological conditions. The company operates globally and currently employs over 200 employees. Basilea's main focus is on developing drugs that meet the specific needs of patients and medical professionals. It works closely with its partners and customers to ensure that its products meet the highest quality standards and meet the demands of patients. Basilea has two main divisions: infections and oncology. The company has a strong expertise in the development of antibiotics and antifungal drugs. One of its most well-known products is the antibiotic Ceftobiprol, which is used to treat bacterial infections such as pneumonia, skin, and bone infections. Another promising product is Isavuconazole, an antifungal drug used to treat fungal infections. In oncology, the business is divided into two important areas: the development and marketing of cancer drugs, and collaboration with other companies to develop tailored cancer therapies. The company works closely with other leading companies such as Pfizer, Roche, and GSK to expand its expertise in cancer research and development. Basilea's business model is based on the development of innovative drugs that meet the needs of patients and doctors. The company invests heavily in its research and development and aims to develop ethically sound and effective solutions for controlling infectious diseases and cancer. Through strategic partnerships and targeted marketing, it works to market its products worldwide and strengthen its position in the rapidly changing pharmaceutical market. Basilea sees itself as an innovative company that establishes itself in the market and plays a leading role in the industry. Its success is based on the concept of innovation, commitment, and growth. The company is committed to improving the quality of life for patients around the world by focusing on the development of new drugs that help fulfill important medical needs. Basilea Pharmaceutica AG remains committed to striving for excellence and innovation together with its partners and customers to advance the development of new treatment options. With this focus, Basilea will continue to play an important role in the industry and bring innovative drugs to the market that improve patients' lives and make the world a better place. Basilea Pharmaceutica AG Allschwil ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Basilea Pharmaceutica AG Allschwil's P/E Ratio

The Price to Earnings (P/E) Ratio of Basilea Pharmaceutica AG Allschwil is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Basilea Pharmaceutica AG Allschwil's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Basilea Pharmaceutica AG Allschwil is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Basilea Pharmaceutica AG Allschwil’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Basilea Pharmaceutica AG Allschwil stock

What is the price-to-earnings ratio of Basilea Pharmaceutica AG Allschwil?

The price-earnings ratio of Basilea Pharmaceutica AG Allschwil is currently 10.96.

How has the price-earnings ratio of Basilea Pharmaceutica AG Allschwil changed compared to last year?

The price-to-earnings ratio of Basilea Pharmaceutica AG Allschwil has increased by -79.41% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Basilea Pharmaceutica AG Allschwil high compared to other companies?

Yes, the price-to-earnings ratio of Basilea Pharmaceutica AG Allschwil is high compared to other companies.

How does an increase in the price-earnings ratio of Basilea Pharmaceutica AG Allschwil affect the company?

An increase in the price-earnings ratio of Basilea Pharmaceutica AG Allschwil would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Basilea Pharmaceutica AG Allschwil affect the company?

A decrease in the price-earnings ratio of Basilea Pharmaceutica AG Allschwil would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Basilea Pharmaceutica AG Allschwil?

Some factors that influence the price-earnings ratio of Basilea Pharmaceutica AG Allschwil are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Basilea Pharmaceutica AG Allschwil pay?

Over the past 12 months, Basilea Pharmaceutica AG Allschwil paid a dividend of 5 CHF . This corresponds to a dividend yield of about 12.47 %. For the coming 12 months, Basilea Pharmaceutica AG Allschwil is expected to pay a dividend of 0 CHF.

What is the dividend yield of Basilea Pharmaceutica AG Allschwil?

The current dividend yield of Basilea Pharmaceutica AG Allschwil is 12.47 %.

When does Basilea Pharmaceutica AG Allschwil pay dividends?

Basilea Pharmaceutica AG Allschwil pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Basilea Pharmaceutica AG Allschwil?

Basilea Pharmaceutica AG Allschwil paid dividends every year for the past 0 years.

What is the dividend of Basilea Pharmaceutica AG Allschwil?

For the upcoming 12 months, dividends amounting to 0 CHF are expected. This corresponds to a dividend yield of 0 %.

In which sector is Basilea Pharmaceutica AG Allschwil located?

Basilea Pharmaceutica AG Allschwil is assigned to the 'Health' sector.

Wann musste ich die Aktien von Basilea Pharmaceutica AG Allschwil kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Basilea Pharmaceutica AG Allschwil from 6/21/2013 amounting to 5 CHF, you needed to have the stock in your portfolio before the ex-date on 4/11/2013.

When did Basilea Pharmaceutica AG Allschwil pay the last dividend?

The last dividend was paid out on 6/21/2013.

What was the dividend of Basilea Pharmaceutica AG Allschwil in the year 2023?

In the year 2023, Basilea Pharmaceutica AG Allschwil distributed 0 CHF as dividends.

In which currency does Basilea Pharmaceutica AG Allschwil pay out the dividend?

The dividends of Basilea Pharmaceutica AG Allschwil are distributed in CHF.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Basilea Pharmaceutica AG Allschwil

Our stock analysis for Basilea Pharmaceutica AG Allschwil Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Basilea Pharmaceutica AG Allschwil Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.